Navigation Links
AccessClosure Announces Launch of New Mynx Cadence™ Vascular Closure Device

MOUNTAIN VIEW, Calif., Jan. 11, 2011 /PRNewswire/ -- AccessClosure, Inc., the U.S. market leader in extravascular closure devices, announced today the launch of its next generation product, the Mynx Cadence Vascular Closure Device (VCD).  With its simpler design and improved ease-of-use, Mynx Cadence offers physicians smoother device deployment while maintaining all the benefits of the original Mynx.


"We are extremely excited about the launch of the Mynx Cadence," said Gregory D. Casciaro, President and CEO of AccessClosure.   "Designing enhanced solutions for vascular closure is our top priority and the design changes incorporated into the Mynx Cadence make it easier to use while maintaining the same feel our users have grown accustomed to.  We believe this device provides an excellent platform for growth as we continue to expand our user base."

Three design changes on the new Mynx Cadence device make it easier and more consistent to deploy.  A definitive shuttle stop when deploying the sealant reduces the possibility of over-shuttling.  Additionally, a single marker on the advancer tube removes any guesswork around sealant compression.  Finally, a new sealant sleeve protects the sealant during deployment and shortens the procedure time by eliminating the need to pre-soak during device preparation.  These changes result in more consistent sealant delivery every time.  

"My initial experience with the Mynx Cadence has been very positive," said Elias Kassab, MD, FACC, an Interventional Cardiologist from Oakwood Hospital in Detroit, Michigan.  "The design changes inspire increased confidence in the device, but I don't feel that I've lost any of the tactile feedback I'm used to with the Mynx.  These changes truly improve the experience of deploying the Mynx."

The Mynx Vascular Closure Device utilizes a conformable, water-soluble polyethylene glycol (PEG) sealant to seal the femoral artery, which dissolves within 30 days, leaving nothing behind but a healed artery. The Mynx received its first FDA approval in May 2007, has been used in over 700,000 procedures, and is available in two sizes for 5F and 6F/7F procedural sheaths.  

AccessClosure will present at the 29th Annual J.P. Morgan Healthcare Conference on Tuesday, January 11, in San Francisco. Gregory D. Casciaro, President and CEO, will address the conference at 4:00 p.m. PST.

About Vascular Closure

There are two methods of closing the femoral artery after cardiovascular procedures – manual compression and vascular closure devices.  Manual compression entails up to 30 minutes of firm manual pressure applied directly to the access site, which is often painful for the patient, followed by many hours of bed rest in a hospital recovery room.  Physicians frequently choose to use a vascular closure device (VCD) as an alternative to manual compression because it stops the bleeding more quickly, thereby allowing patients to leave the hospital earlier.

However, despite the benefits of VCDs, many patients find that deployment of a VCD is extremely painful.  The Mynx addresses this shortcoming by eliminating the tugging and cinching of the artery that occurs with other closure devices.  The sealant is designed for gentle placement on top of the artery without the use of a suture or permanent metal implant.  

About AccessClosure

Founded in 2002, AccessClosure, Inc. is a privately held medical device company pioneering innovative access site management products designed to provide a reliable, patient-friendly vascular closure experience.  For more information, visit our website at

SOURCE AccessClosure, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. AccessClosure Announces Distribution Agreement for Radial Compression Band
2. STAAR Surgical Announces Fourth Quarter 2010 Revenue Expected to Exceed $14.2 Million
3. Mithridion, Inc. Announces New Funding and Outlines Strategy for Central Nervous System Drug Development
4. Nalco Announces Price Increase
5. Vasomedical Announces Launch of Its Online Company Store
6. Mindray Medical Announces Preliminary 2010 Operating Results
7. Mindray Medical Meets 2010 Product Development Targets and Announces Strong 2011 Pipeline
8. Shionogi Inc. Announces Commercial Availability of KAPVAY™ (clonidine hydrochloride) Extended-Release Tablets for the Treatment of ADHD
9. Optimer Pharmaceuticals Announces Key Additions to Management Team
10. Auxilium Pharmaceuticals Reports Preliminary Fourth Quarter 2010 Net Revenue and Announces 2011 XIAFLEX Revenue Guidance
11. TriReme Medical Announces Japanese Alliance
Post Your Comments:
(Date:6/26/2016)... 27, 2016  VMS Rehab Systems, Inc. ( ... whatever measures required to build a strong and stable ... currently listed on the OTC Markets-pink current trading platform. ... CEO, "We are seeing an anomaly in market trading ... only by the Company, but shareholders and market players ...
(Date:6/24/2016)... N.C. , June 24, 2016  Consumers ... decisions and regulators/payers have placed more emphasis on ... environment, patient support programs in the pharmaceutical industry ... patients, medications. Consequently, pharmaceutical companies are focusing on ... they are providing products and services that improve ...
(Date:6/24/2016)... FRANCISCO, Calif. , June 24, 2016 /PRNewswire/ ... ), a biopharmaceutical company developing novel therapeutics for ... unmet needs, today announced the closing of its ... of common stock, at the public offering price ... in the offering were offered by GBT. GBT ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... , ... The temporary closing of Bruton Memorial Library on June 21 due to a possible ... often overlooked aspect of head lice: the parasite’s ability to live away from a human ... but a necessary one in the event that lice have simply gotten out of control. ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. ... from injury. Recently, he has implemented orthobiologic procedures as a method for treating ... one of the first doctors to perform the treatment. Orthobiologics are substances that ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
(Date:6/24/2016)... ... June 24, 2016 , ... People across the U.S. are sharpening their pencils ... an essay contest in which patients and their families pay tribute to a genetic ... 2016 National Society of Genetic Counselors (NSGC) Annual Education Conference (AEC) this September. ...
Breaking Medicine News(10 mins):